DDO-5936

DDO-5936

D655177-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer In Vitro DDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group . DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 0~80 mg/kg Administration: P.o. Result: Showed a moderate effect at the high dose group. IC50& Target:Hsp90-Cdc37 PPI

DDO-5936 是一种强效的特异性 Hsp90-Cdc37 PPI 抑制剂。DDO-5936 可用于结直肠癌的研究。

2355377-13-6(DMSO)

C25H29N5O4S

495.6 g/mol

CC1=CC(=C(C(=C1)C)S(=O)(=O)N(CC(=O)O)C2=CC=C(C=C2)NC3=NC(=NC=C3)N4CCCC4)C